Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2− Breast Cancer
Authors:
- Rahat AlamRARahat Alam
- Anna RevaARAnna Reva
- David G. EdwardsDEDavid G. Edwards
- Bree M. LegeBLBree M. Lege
- Laura S. Munoz-ArcosLMLaura S. Munoz-Arcos
- Carolina ReduzziCRCarolina Reduzzi
- Swarnima SinghSSSwarnima Singh
- Xiaoxin HaoXHXiaoxin Hao
- Yi-Hsuan WuYWYi-Hsuan Wu
- Zeru TianZTZeru Tian
- Laura M. NataleeLNLaura M. Natalee
- Gargi DamleGDGargi Damle
- 21 January 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (4) , 818-837
Abstract
Bone metastases can disseminate to secondary sites and promote breast cancer progression, creating additional clinical challenges. The mechanisms contributing to secondary metastasis are barely understood. Here, we evaluate the prediction power of HER2-expressing (HER2E) circulating tumor cells (CTC) after analyzing over 13,000 CTCs from a cohort of 137 patients with metastatic breast cancer with initial HR+/HER2− status and use preclinical models of bone metastasis (BM) to validate the role of HER2E CTCs in multiorgan metastases. Although HER2 expression was higher in patients with BM, experimental analyses revealed that HER2E CTCs derived from bone lesions were more dependent on HER2 activity and more susceptible to anti-HER2 therapy. Targeting the bone-mediated HER2 induction reduces CTC detection and abrogates secondary metastasis from the bone. Overall, we elucidate that HER2E CTCs can serve as a noninvasive biomarker for BM formation with high therapeutic benefit for patients with HR+ metastatic breast cancer. Significance: Given the urgent need for alternative strategies to block metastasis progression, we demonstrate that blocking HER2-mediated secondary metastasis improves clinical outcome and establish HER2 as a biomarker for bone metastasis in patients with initial HR+/HER2− breast cancer, which represents ∼70% of all cases.Keywords
All Related Versions
Funding Information
- National Cancer Institute (K99CA263033-01A1)
- National Cancer Institute (4R00CA263033-02)
- Breast Cancer Research Foundation (23-20-26-BADO)
- Breast Cancer Alliance
- U.S. Department of War (BC201371P1)
- National Cancer Institute (R01CA183878)
- National Cancer Institute (R01CA251950)
- National Cancer Institute (U01 CA253553)
- National Institutes of Health (P30CA196521)
- National Institutes of Health (S10OD026880)
- National Institutes of Health (S10OD018033)
- National Institutes of Health (S10OD023469)
- National Institutes of Health (S10OD025240)
- Common Fund (U54CA267776)
- Cancer Prevention and Research Institute of Texas (CPRIT-RP180672)
- U.S. Department of War (W81XWH-21-1-0790)
This publication has 58 references indexed in Scilit:
- Overcoming Endocrine Resistance in Breast CancerCancer Cell, 2020
- The Genomic Landscape of Endocrine-Resistant Advanced Breast CancersCancer Cell, 2018
- Systematic Functional Annotation of Somatic Mutations in CancerCancer Cell, 2018
- ggplot22016
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted TherapyCancer Cell, 2016
- The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer CellsCancer Cell, 2015
- The Histone Deacetylase SIRT6 Is a Tumor Suppressor that Controls Cancer MetabolismCell, 2012
- An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor ReceptorCell, 2006
- Upregulation of CXCR4 is essential for HER2-mediated tumor metastasisCancer Cell, 2004
- ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancerCancer Letters, 1994